

Minocycline Reduces Proinflammatory Cytokine Expression, Microglial Activation, and Caspase-3 Activation in a Rodent Model of Diabetic Retinopathy

J. Kyle Krady,¹ Anirban Basu,¹ Colleen M. Allen,¹ Yuping Xu,² Kathryn F. LaNoue,² Thomas W. Gardner,² and Steven W. Levison^{1,3}

Diabetes leads to vascular leakage, glial dysfunction, and neuronal apoptosis within the retina. The goal of the studies reported here was to determine the role that retinal microglial cells play in diabetic retinopathy and assess whether minocycline can decrease microglial activation and alleviate retinal complications. Immunohistochemical analyses showed that retinal microglia are activated early in diabetes. Furthermore, mRNAs for interleukin-1 β and tumor necrosis factor- α , proinflammatory mediators known to be released from microglia, are also increased in the retina early in the course of diabetes. Using an in vitro bioassay, we demonstrated that cytokine-activated microglia release cytotoxins that kill retinal neurons. Furthermore, we showed that neuronal apoptosis is increased in the diabetic retina, as measured by caspase-3 activity. Minocycline represses diabetes-induced inflammatory cytokine production, reduces the release of cytotoxins from activated microglia, and significantly reduces measurable caspase-3 activity within the retina. These results indicate that inhibiting microglial activity may be an important strategy in the treatment of diabetic retinopathy and that drugs such as minocycline hold promise in delaying or preventing the loss of vision associated with this disease. *Diabetes* 54:1559–1565, 2005

Diabetic retinopathy is a progressive neurological disease characterized by degeneration of neurons and macroglia and accompanied by profound vascular changes that eventually lead to legal blindness. Despite progress in understanding the

From the ¹Department of Neural and Behavioral Sciences, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; the ²Department of Cellular and Molecular Physiology, The Pennsylvania State University College of Medicine, Hershey, Pennsylvania; and the ³Department of Neurology and Neuroscience, University of Medicine and Dentistry in New Jersey, New Jersey Medical School, Newark, New Jersey.

Address correspondence and reprint requests to J. Kyle Krady, PhD, Dept. of Neural and Behavioral Sciences, H109, The Pennsylvania State University College of Medicine, Hershey, PA 17033. E-mail: jkk7@psu.edu.

Received for publication 3 November 2004 and accepted in revised form 27 January 2005.

AMC, 7-amino-4-methyl coumarin; CNS, central nervous system; COX-2, cyclo-oxygenase-2; DAPI, 4',6-diamidino-2-phenylindole; IL, interleukin; LDH, lactate dehydrogenase; MEM, minimum essential medium; MMP, matrix metalloproteinases; NCS, newborn calf serum; ROS, reactive oxygen species; STZ, streptozotocin; TNF- α , tumor necrosis factor- α ; TUNEL, transferase-mediated dUTP nick-end labeling; VEGF, vascular endothelial growth factor.

© 2005 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

pathogenesis of diabetic retinopathy, our knowledge of the mechanisms leading to neuronal cell loss, glial dysfunction, and vascular remodeling is incomplete. Whereas the retina has traditionally been viewed as an immune privileged tissue, evidence is accumulating to support a role for local inflammation in the pathogenesis of diabetic retinopathy. For example, alterations in the level of adhesion molecules, which facilitate the trafficking of leukocytes into the retina, accompany changes in retinal blood vessel permeability (1). Jousen et al. (2) identified tumor necrosis factor- α (TNF- α) and cyclo-oxygenase-2 (COX-2), two proinflammatory mediators, as operative in the early signature pathologies of diabetic retinopathy. In addition, Funatsu et al. (3) documented local production of interleukin (IL)-6 in the vitreous humor of diabetic patients and showed that levels of IL-6 correlate with the severity of retinal pathophysiology.

Elevated levels of cytokines can activate the endogenous immune cells of the central nervous system (CNS), cells known as microglia. Microglia are related to dendritic cells in other tissues and, although similar to macrophages, are a distinct cell type (4). In response to an activating stimulus, quiescent microglia undergo a series of stereotyped morphological, phenotypical, and functional changes (5). In response to signals from dying cells, activated microglia evolve into phagocytes capable of clearing debris (6). It is yet to be determined what signals during diabetes activate the retinal microglia, whether microglial activation precedes the major histopathologic changes that occur in the retina, and what affect these microglia may play in the pathophysiology of the disease.

In this study, we examined the putative role of microglia and inflammation in the progression of early diabetic retinopathy and tested the ability of the drug, minocycline, to abrogate some of the negative consequences of microglial activation. Minocycline is a second-generation, semi-synthetic tetracycline that exerts anti-inflammatory effects that are completely separate from its antimicrobial actions. Studies suggest that it affords neuroprotection because it crosses the blood-brain barrier, inhibits the proliferation and activation of microglia, and inhibits apoptosis (7). It has proven effective in a number of animal models of neurodegeneration in which microglia and inflammation have been implicated, but it has yet to be tested in animal models of diabetes. Because minocycline is well tolerated, it represents a potential new therapeutic

tool for preventing or controlling the neurological complications of diabetes.

RESEARCH DESIGN AND METHODS

After a 12-h fast, SD rats weighing ~200 g received a single 60 mg/kg intraperitoneal injection of streptozotocin (STZ; Sigma, St. Louis, MO) in 10 mmol/l sodium citrate buffer (pH 4.5). Control animals were fasted and received the buffer alone. Animals with blood glucose levels >250 mg/dl 4 days after receiving STZ were considered to be diabetic. Blood glucose levels were checked weekly. All experiments abided by the Association for Research in Vision and Ophthalmology statement on the Use of Animals in Ophthalmology and Vision Research and were approved by the Animal Care and Use Committee of the Pennsylvania State University.

For the *in vivo* minocycline (Sigma) treatment, rats were given the drug at a dosage of 45 mg/kg every 12 h the 1st day and 22.5 mg/kg every subsequent 12 h. Vehicle was injected every 12 h for the length of the experiment.

Cell culture. Primary microglial cultures were obtained from SD rats on postnatal day 0–2 (8). Microglial cultures were maintained in Eagle's minimum essential medium (MEM) supplemented with 0.66 mg/ml BSA, 10 ng/ml D-biotin, 5 ng/ml insulin, 5 ng/ml selenium, 5 µg/ml iron-poor transferrin, 2 mmol/l glutamine, 15 mmol/l HEPES buffer, and 100 units · 100 µg⁻¹ · ml⁻¹ penicillin/streptomycin (MCDM). Microglia were maintained in MCDM with 0.5% FCS for 24 h then placed in serum-free MCDM for 16 h. The retinal neuronal R28 cell line was maintained in defined medium containing MEM supplemented with 5 ng/ml insulin, 20 nmol/l progesterone, 100 µmol/l putrescine, 5 ng/ml selenium, 50 µg/ml apo-transferrin, and 50 units · 50 ng⁻¹ · ml⁻¹ penicillin/streptomycin (MN1A) containing 1% newborn calf serum. Culture supplements were purchased from Sigma or Invitrogen (Carlsbad, CA).

Immunofluorescence. Diabetic and matched control rats (*n* = 4 each group) were anesthetized with 75 mg/kg ketaset and 15 mg/kg xylazine 4 weeks after diabetes was induced, after which transcardial perfusion with heparinized culture medium was begun. The rats' eyes were removed, punctured 1 mm posterior to the limbus with a 30-gauge needle, and immersed for 1 h at room temperature in 4% buffered formaldehyde. The eyes were washed in three changes of PBS, cryoprotected in 2.5 mol/l sucrose, and frozen. Cryostat sections (12 µm) were thaw mounted onto Superfrost Plus glass slides and stored at -20°C until use. Sections were blocked in 10% BSA, 10% normal goat serum in Tris buffer for 1 h, then incubated overnight at 4°C with rabbit anti-Iba-1 (Wako Pure Chemical, Wako, TX; 1/500) diluted in 1/5 blocking solution supplemented with 0.2% Triton X-100. Sections were rinsed extensively in Tris-buffered saline with 0.05% Triton X-100, incubated for 2 h with biotinylated secondary antibody, then rinsed and incubated in streptavidin-lissamine rhodamine B sulfonyl chloride and 4',6-diamidino-2-phenylindole (DAPI; 0.5 µg/ml) diluted in 10% BSA. After being washed, sections were coverslipped with aquamount, dried, and viewed using a Leica SP-2 confocal microscope.

RNA isolation from rat retinas and real-time PCR analysis. Rats were anesthetized with ketaset and xylazine. Their retinas were removed, frozen in liquid nitrogen, and stored at -80°C. RNA was isolated using TriReagent (Molecular Research Center, Cincinnati, OH) according to the manufacturer's protocol. Then 2 µg of total RNA were reverse transcribed using the Omniscript RT kit from Qiagen (Valencia, CA). LUX primers to rat TNF-α, rat IL-1β mRNA, and 18S RNA were designed and purchased from Invitrogen. Real-time PCR reactions were performed using 1–3 µl of template and the Platinum qPCR super-mix kit from Invitrogen. Reactions were run on an ABI PRISM 7700 Sequence Detection System. The 18S primers were used to assess treatment-dependent changes in mRNA amounts, and differences in the data for mRNA expression of IL-1β and TNF-α were analyzed using REST software (9).

Western blot analysis of cyclo-oxygenase-2. Microglial cultures were treated with rmTNF-α (5 ng/ml), rmIL-1β (5 ng/ml), or rmIL-6 (5 ng/ml) purchased from R&D Systems (Minneapolis, MN) with or without minocycline (20 nmol/l) for 18 h. After the treatment, cultures were rinsed extensively with PBS and the cells were lysed in buffer containing 1% Triton X-100, 10 mmol/l Tris-HCl (pH 8.0), 150 mmol/l NaCl, 0.5% Nonidet P-40, 1 mmol/l EDTA, 0.2% EGTA, 0.2% sodium orthovanadate, and protease inhibitor cocktail (Sigma). DNA was sheared and the lysate was incubated on ice for 30 min before being centrifuged at 10,000g for 15 min at 4°C. Protein levels were determined using the BCA colorimetric assay (Pierce, Rockford, IL). Then 15 µg of protein were separated on 8% polyacrylamide gels, electrophoresed, and transferred onto nitrocellulose membranes. Membranes were blocked (Roche Blocking Solution, Indianapolis, IN), incubated overnight at 4°C in anti-COX-2 (Santa Cruz Biotechnology, Santa Cruz, CA), extensively washed, incubated with 2° antibody conjugated to horseradish peroxidase, and developed using Renaissance Chemiluminescence (Du Pont-NEN Life Science). Images were obtained

and quantified using a UVP imaging system with LabWorks software (UVP, Upland, CA).

Coculturing microglia with retinal neurons. Microglia were plated at 1 × 10⁵ cells/well into polycarbonate transwell inserts (1.0 cm²) with a 0.4-µm pore size (Corning, Corning, NY). After 24 h in MCDM with 0.5% serum, the cells were switched to serum-free MCDM for 12 h. Microglia were then treated one of four ways: 1) left untreated in serum-free MCDM, 2) treated with 20 nmol/l minocycline for 1 h before being returned to MCDM for 6 h, 3) treated with 10 ng/ml TNF-α for 6 h, or 4) treated with 20 nmol/l minocycline for 1 h before being stimulated with 10 ng/ml TNF-α for 6 h. Minocycline was present for only 1 h. After being treated, microglia were washed three times with PBS to remove drug and/or cytokine and the Transwells were placed in wells containing R28 cells. R28 cells were plated onto laminin-coated coverslips at a density of 5 × 10⁴ cells/well in MN1A containing 1% newborn calf serum (NCS) for 24 h. The R28 cells were then differentiated with 250 µmol/l dibutyl cAMP in MN1A with 1% NCS for 24 h. After being differentiated, the cells were washed two times with PBS and the R28 cells were placed in MN1A with 1% NCS. After being cocultured for 48 h, cell culture supernatants were assayed for lactate dehydrogenase (LDH) levels (Sigma) according to the manufacturer's protocol. The coverslips containing R28 cells were rinsed three times with PBS, and the cells were fixed with 3% paraformaldehyde for 10 min. The coverslips were then processed for transferase-mediated dUTP nick-end labeling (TUNEL) according to previously published protocols (10).

Active caspase-3 assay. Rats were anesthetized with pentobarbital sodium (Nembutal; Abbott; 0.1g/kg) and then decapitated. Their retinas were excised immediately and sonicated on ice in 100 µl of lysis buffer (25 mmol/l HEPES [pH 7.5], 5 mmol/l MgCl₂, 5 mmol/l EDTA, 5 mmol/l dithiothreitol, 1% Nonidet P-40) that contained one tablet per 10 ml of complete EDTA-free protease inhibitor cocktail (Roche). The sonication was followed by a 20-min incubation at 4°C and centrifugation at 15,000g at 4°C. Caspase-3 activity was measured in the supernatants, with enzyme activity normalized to protein content as measured by a Bio-Rad protein assay (Bio-Rad, Hercules, CA).

The Fluorometric CaspACE Assay System was purchased from Promega (Madison, WI) and used according to the manufacturer's directions for the 96-well plate assay format with minor modifications (incubations were performed at 37°C instead of 30°C). Duplicate assays were performed for each sample, with blanks and negative controls. A 7-amino-4-methyl coumarin (AMC) standard curve was run with each group of unknowns. Fluorescence was measured using a SpectraMAX Gemini XS (Molecular Devices, Sunnyvale, CA) fluorescence plate reader at an excitation wavelength of 360 nm and an emission wavelength of 460 nm. Caspase-3 enzyme activity is expressed as picomoles of AMC liberated per milligram of protein per minute.

RESULTS

Microglia become activated early in the course of diabetic retinopathy. It has been postulated that inflammation plays an integral role in the etiology of diabetic retinopathy. Microglia, as the immune-effector cells within both the CNS and retina, might be expected to have an important role in initiating this inflammatory response. To determine whether microglia become activated early in the course of diabetic retinopathy, we used immunofluorescence to characterize the microglia in the retina of rats with STZ-induced diabetes. Diabetic rats and age-matched controls were killed 4 weeks after receiving a single intraperitoneal dose of STZ, and their eyes were isolated and stained for Iba-1, a calcium-binding protein expressed by microglial cells. In control retinas, the microglia possessed thin processes that branched several times as they extended 10–30 µm from the cell soma (Fig. 1). This morphology is characteristic of resting microglia. In contrast, microglia in the retinas of the diabetic rats appeared activated. Their cell bodies were hypertrophied, they had fewer processes, and those processes were thicker and shorter. In some cases, microglia in the diabetic retinas were amoeboid with few or no processes, consistent with differentiation toward a phagocyte. At this early stage, only a subpopulation of the microglia in the diabetic retinas appeared activated. Microglia in both control and diabetic retinas appeared primarily in the granular cell layer, and




FIG. 1. Microglia in the retina become activated in STZ-induced diabetes. Retinas from control and diabetic rats were isolated, sectioned, and processed for Iba-1 (red), an antigen specific for microglia, and counterstained with DAPI (blue) 4 weeks after diabetes was induced. Microglia in the control retinas possessed long, thin processes characteristic of ramified microglia (A and B). Microglia in the retinas of diabetic rats displayed shorter, thicker processes indicative of an activated phenotype (C and D). B and D represent fivefold enlargements of sections of A and C.

no gross differences in distribution or cell number were observed between the two conditions. Our results indicated that diabetes leads to an early activation of microglia within the inner retina and that activation occurs locally in response to diabetes and not globally throughout the retina.

Diabetes increases the expression of mRNAs for IL-1 β and TNF- α in the retina. Because microglia can produce cytokines as a consequence of activation, we measured changes in the relative levels of two proinflammatory cytokine mRNAs in the retinas of rats during STZ-induced diabetes. Total RNA was extracted from isolated retinas and used as template for real-time PCR analysis; the real-time PCR analysis was performed for IL-1 β and TNF- α . As a reference, primers to 18S RNA were used. Real-time PCR was performed on six retinas per group in duplicate. Results were analyzed using REST software, which calculates the confidence levels of real-time data. Our analysis revealed increased expression of both TNF- α and IL-1 β mRNA in retinas from diabetic rats compared with retinas of controls (Fig. 2). TNF- α mRNA levels were increased 6-fold over those of controls, whereas IL-1 β mRNA levels increased 4.5-fold.

Next, diabetic rats were treated with minocycline (22.5

mg/kg, i.p.) twice daily beginning 3 days after STZ injection. mRNA levels of TNF- α and IL-1 β were measured 2 weeks later by real-time PCR. Minocycline treatment abrogated the increases in mRNA expression seen as a result of diabetes for both cytokines. Minocycline-treated animals had 50% lower mRNA levels of TNF- α and 40% lower levels of IL-1 β . These results confirmed that diabetes causes an early increase in the expression of inflammatory mediators within the retina and showed that minocycline treatment reduces this inflammatory component.

Minocycline prevents TNF- α -induced COX-2 expression in microglia. To further characterize minocycline's effect on inflammation, we designed experiments to assess minocycline's ability to affect the production of other proinflammatory stimuli. For these experiments, microglial cultures with proinflammatory cytokines were pre-treated with or without 20 nmol/l minocycline. Previous dosage-response experiments showed that this dosage of minocycline provides maximal protection to neuronal cultures treated with 500 μ mol/l glutamate and significantly reduces proliferation and nitric oxide (NO) and IL-1 β release from similarly treated purified microglial cultures (7). Minocycline was added 1 h before treatment with cytokines. Then 24 h after cytokine treatment, cul-




FIG. 2. Minocycline abrogates the increased retinal expression of TNF- α and IL-1 β mRNAs as a consequence of diabetes. Rats received minocycline (mino; 22.5 mg/kg, i.p.) twice daily for 2 weeks beginning 3 days after STZ injection. RNA was isolated from the retinas and analyzed by real-time PCR. Primers for 18S RNA were used to calibrate changes in mRNA expression. REST software was used for statistical analysis. * $P < 0.001$ for diabetic vs. control animals; ** $P < 0.05$ for diabetic vs. minocycline-treated diabetic animals.




FIG. 3. Minocycline blocks TNF- α -induced COX-2 expression in rat microglial cultures. Microglia were treated with cytokines with or without minocycline (mino; 20 nmol/l) for 18 h. Cell lysates were analyzed for COX-2 by Western blot. **A:** Representative blot of COX-2. **B:** Graphic representation of the densitometry readings from three separate experiments. Data are averages \pm SE. Increases in COX-2 vs. untreated (UT) cultures were significant ($P < 0.01$) by Student's *t* test. The level of COX-2 in the minocycline plus TNF- α treated group was not significant from controls.

tures were rinsed with PBS and the cells were lysed. Cell lysates were electrophoresed on SDS-PAGE gels, electroblotted onto nitrocellulose membranes, and probed with antibody to the COX-2 protein. COX-2 is an enzyme important in prostaglandin synthesis and is a robust marker of inflammation. The cytokines IL-1 β , TNF- α , and IL-6 all induced COX-2 expression approximately fivefold compared with control microglial cultures (Fig. 3). Pretreatment with minocycline completely prevented the induction of COX-2 expression from TNF- α -treated microglia, but minocycline did not affect the increase in COX-2 stimulated by IL-1 β or IL-6.

Minocycline prevents retinal neuronal cell death by activated microglia. Activated microglia produce a number of compounds such as oxygen and nitrogen free radicals that are cytotoxic. To determine whether microglia produce cytotoxins that could kill retinal neurons and whether minocycline could prevent this microglial cytotoxicity, we cocultured cytokine-activated microglia with differentiated R28 retinal neuronal cells. Microglial cultures were grown on transwell filters and activated by TNF- α treatment. Some cultures were pretreated with minocycline. Cytokine treatment lasted for 6 h, after which the microglial cells were rinsed extensively. The inserts containing activated microglia were then incubated with

R28 cells for 48 h. Additional incubation times were tested; however, the 48-h time point exhibited the largest difference in R28 cell death between cells cocultured with untreated microglia and those cocultured with TNF- α -activated microglia. After 48 h, cell supernatants were assayed for LDH as a measure of cell death, and the R28 cells were fixed and processed for TUNEL as a measure of apoptotic cell death. Microglia activated by TNF- α produced toxic substances that caused a 2.5-fold increase in R28 cell death as measured by LDH activity (Fig. 4). Minocycline pretreatment almost completely blocked the increase in cell death. Similar results were seen when TUNEL was used as an index of apoptotic cell death. R28 cells exhibited ninefold higher TUNEL staining when they were cocultured with TNF- α -activated microglia as opposed to untreated microglia. Again, pretreatment with minocycline significantly blocked the effects of TNF- α -induced cytotoxicity of the microglial cells. TNF- α alone did not induce the death of R28 cells. These results provide further evidence that minocycline can abrogate the negative aspects of microglial activation.

Minocycline can prevent diabetes-induced apoptosis in the retina. To further characterize minocycline's effects on apoptosis, we assessed the ability of systemic minocycline treatment to decrease the activation of caspase-3 within the retina in adult SD rats with STZ-induced diabetes. In these studies, 3-month, STZ-induced diabetic animals were injected with 22 mg/kg of minocycline twice daily for 10 days. Protein lysates from the retinas of treated or untreated diabetic rats or treated or untreated euglycemic rats were assayed for caspase-3 activity as a measure of apoptosis. Caspase-3 activity increased 50% within the retina of diabetic compared with control animals (Fig. 5). Minocycline treatment for 10 days significantly abrogated the increase in caspase-3 activity ($P < 0.004$). There was no statistical difference between the levels of caspase-3 activity in control animals administered vehicle and diabetic animals administered minocycline. Minocycline had no effect on caspase-3 activity in the retinas of euglycemic rats. The blood glucose of control rats given vehicle and those given minocycline was 7.1 ± 0.3 and 7.1 ± 0.2 mmol/l, respectively; the levels of diabetic rats given vehicle and those given minocycline were 24.7 ± 0.6 and 24.3 ± 0.9 mmol/l, respectively. These experiments demonstrated that short-term treatment with minocycline late in diabetes can significantly reduce apoptosis within the retina.

DISCUSSION

The goal of this study was to determine whether retinal microglia become reactive as a consequence of diabetes, leading to the release of soluble cytotoxins that contribute to the progression of diabetic retinopathy. We also evaluated the efficacy of minocycline in abrogating the retinal cell death that occurs as a consequence of diabetes. We showed that 1) microglia become activated before the onset of neuronal cell death; 2) diabetic conditions lead to an elevation of proinflammatory cytokine expression within the retina; 3) proinflammatory cytokines such as TNF- α can directly activate microglia, leading to their producing cytotoxins that will kill retinal neurons; 4) minocycline decreases the release of these cytokines, resulting in neu-




FIG. 4. Minocycline blocks R28 neuronal cell death mediated by TNF- α -activated microglia. Microglia were grown in the upper chambers of transwells and treated with TNF- α (5 ng/ml) for 6 h. Minocycline (mino; 20 nmol/l) was added to select microglial cultures 1 h before TNF- α treatment. After being extensively rinsed, the microglia were cultured above differentiated R28 neuronal cultures for 48 h. A–D: Representative fields of R28 cells processed for TUNEL staining 48 h after being cocultured with untreated (UT) microglia (A), untreated microglia pretreated with minocycline (B), TNF- α -treated microglia (C), and TNF- α -treated microglia pretreated with minocycline (D). Also shown are counts of TUNEL+ cells (E) and LDH supernatant levels (F) from two separate experiments performed in triplicate. Data are means \pm SE. $P < 0.005$ for TNF- α -treated vs. control by ANOVA followed by the Bonferroni post hoc test.

roprotection in vitro; and 5) minocycline decreases the expression of proinflammatory cytokines in an animal model of diabetes and decreases the levels of active caspase-3, thus affording neuroprotection in vivo.

Microglia are sentinels within the central nervous system. Our analysis of retinal microglial activity in STZ-induced diabetes confirms observations by others (11,12). Microglia clearly exhibited a more reactive phenotype 4 weeks after diabetes was induced with STZ. However, we did not observe global microglial reactivity within the retina. Instead, we observed patches of locally activated microglia, suggesting that there are hot spots in the retina that experience elevated stress as a consequence of diabetes. Although resting microglia promote and maintain homeostasis in the normal CNS, reactive microglia have been implicated in the progression of many neurological diseases, including Alzheimer disease, multiple sclerosis, HIV-related dementia, and stroke (13–18). Microglial-mediated cytotoxicity appears to be involved in the tissue damage and functional loss seen in these diseases

by the release of reactive oxygen and reactive nitrogen species, cytokines, excitotoxins, and proteases.

Although few studies have associated microglial activation with the pathogenesis of diabetic retinopathy, a strong case can be made for inflammation. Elevated IL-6 and IL-8 have been documented in the vitreous fluid of patients with diabetic retinopathy (19), and TNF- α has been shown to be elevated in the serum (19) and epiretinal membranes (20) of patients with diabetic retinopathy. In addition, platelets from patients with active proliferative diabetic retinopathy express higher than normal levels of TNF- α and its receptors, TNF-RI and TNF-RII (21). The expression of intracellular adhesion molecule (ICAM)-1 is increased early in diabetic retinopathy and has been associated with increased TNF- α , leukostasis, and subsequent endothelial cell death characteristic of the disease (2,21,22). Increased levels of IL-1 β have also been measured in the retinas of STZ-induced diabetic rats and correlate with elevated levels of the inducible isoform of NO synthase (23). In addition, nonsteroidal anti-inflamma-




FIG. 5. Minocycline attenuates the increase in retinal caspase-3 activity. A single dose of STZ was used to induce diabetes in rats. Then 3 months after diabetes induction, a subset of rats was treated twice daily for 10 days with minocycline (22.5 mg/kg, i.p.). Protein lysates from isolated retinas were analyzed for caspase-3 activity. Data are means \pm SE. * $P < 0.003$ as assessed by ANOVA followed by post hoc *t* test with Bonferroni correction. There was no statistical difference between control animals administered vehicle and diabetic animals administered minocycline.

tory drugs have been shown to prevent the changes in ICAM-1 and integrin expression associated with diabetic retinopathy via TNF- α suppression and to decrease vascular leukostasis and blood-retinal barrier breakdown (24). These study findings suggest that cytokines and the resulting neuroinflammation cause several of the hallmark features of diabetic retinopathy.

Microglia release numerous cytotoxic molecules in response to cytokines. There are strong data implicating cytokines in microglial activation. Cytokines such as IL-1 β , γ -interferon, TNF- α , and IL-6 have been shown to directly activate microglia (25–27). For example, TNF- α decreases cAMP levels within microglia, leading to a more destructive phenotype (28). Our results confirm the induction of proinflammatory cytokines TNF- α and IL-1 β within the retina as a result of STZ-induced diabetes. The most likely source of these cytokines are retinal microglia; however, other retinal cell types (e.g., pericytes) release proinflammatory cytokines in response to diabetic stress (29). Upon their release, these cytokines can propagate the inflammatory response within the retina, leading to increased leukocyte infiltration. Given their functions, these signals represent targets for therapeutic interventions.

Activated microglia release soluble effectors that can directly or indirectly cause damage to neural cells. Microglia release IL-1 β , IL-3, IL-6, TNF- α , vascular endothelial growth factor (VEGF), lymphotoxin, macrophage inflammatory protein-1 α , matrix metalloproteinases (MMPs), NO, and reactive oxygen species (ROS) (30–32). The cytokines IL-1 β , IL-6, TNF- α , and lymphotoxin alter expression of vascular cell adhesion molecules to recruit lymphocytes and macrophages to injury sites (33). In addition, lymphotoxin, TNF- α , NO, and ROS can directly kill cells. TNF- α has been shown to induce the death of neurons via a direct apoptotic effect after receptor binding and by directly interfering with intracellular substrates used by growth factors such as IGF-I and the insulin receptor (34,35). VEGF, NO, and MMPs can weaken the blood-retinal barrier, thus enhancing the infiltration of leukocytes into the CNS.

Minocycline as a potential new therapeutic tool to prevent diabetic retinopathy. Recent reports have shown that diabetic retinopathy involves a chronic, low-grade inflammatory component (3,36–38). Elevated cytokines activate microglia, thereby stimulating a cycle of inflammation that recruits leukocytes, causes vascular breakdown, and directly induces cell death through the release of cytotoxic substances. Our in vitro bioassay data clearly demonstrated the ability of activated microglia to release soluble factors that can cause neuronal death. Moreover, the microglia appear to become activated coincident with the increase in apoptosis documented within the diabetic retina (39). Microglia, therefore, appear to be implicated in a number of the pathologies associated with diabetic retinopathy, including vascular complications, neuronal death, and glial dysfunction. Drugs designed to counter these negative aspects of microglial activation should, therefore, have numerous benefits in diseases such as diabetic retinopathy.

Minocycline is effective in a number of animal models of neurodegeneration in which microglia and inflammation have been implicated. Minocycline dramatically reduces inflammation and protects against excitotoxic neuronal death after cerebral ischemia (40,41) and photoreceptor

degeneration (42). It provides this neuroprotection in part by inhibiting the proliferation and activation of microglia (7). Results from our in vivo experiments indicate that minocycline reduces the expression of inflammatory mediators and the incidence of apoptosis within the retina as a consequence of diabetes. In addition to direct actions on microglia, minocycline also has been shown to exert antiapoptotic effects by inhibiting caspases-1 and -3 and the release of cytochrome *c* from mitochondria (43–45). These actions likely contributed to our in vivo finding of reduced caspase-3 activity. However, it is unlikely that they explain all of the beneficial effects of minocycline, as we demonstrated decreased proinflammatory gene expression with minocycline treatment at 2 weeks of STZ-induced diabetes. Because minocycline's anti-inflammatory and antiapoptotic effects will be beneficial in reducing the severity of retinal changes induced by diabetes, there is evidence to support the administration of minocycline for treating diabetic retinopathy. Early inhibition of microglial activity would attenuate inflammation, slowing the progression of leukostasis and vascular damage, whereas minocycline's antiapoptotic effects, compounded with a decrease in the release of cytotoxic compounds by activated microglia, would prevent the neuronal death seen later as retinopathy progresses. Although further studies are required to test the prediction that minocycline will reduce vascular permeability in the retina, the studies presented here recommend minocycline as a strong candidate for further consideration as a therapeutic drug in reducing the retinal complications of diabetes.

ACKNOWLEDGMENTS

This work was supported by a program project grant from the Juvenile Diabetes Research Foundation (#4-2002-455, project 5).

The authors express their thanks to Alistair Barber and Rhona Ellis for assistance with the confocal microscopy.

Parts of this study were presented at the annual meeting of the Association for Research in Vision and Ophthalmology, Ft. Lauderdale, Florida, 25–29 April 2004 (Krady 2004 poster session 378:3,234 [available at www.arvo.org]).

REFERENCES

1. Miyamoto K, Khosrof S, Bursell SE, Rohan R, Murata T, Clermont AC, Aiello LP, Ogura Y, Adamis AP: Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. *Proc Natl Acad Sci U S A* 96:10836–10841, 1999
2. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP: Leukocyte-mediated endothelial cell injury and death in the diabetic retina. *Am J Pathol* 158:147–152, 2001
3. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S: Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. *Am J Ophthalmol* 133:70–77, 2002
4. Giulian D, Li J, Bartel S, Broker J, Li X, Kirkpatrick JB: Cell surface morphology identifies microglia as a distinct class of mononuclear phagocyte. *J Neurosci* 15:7712–7726, 1995
5. Streit WJ, Graeber MB, Kreutzberg GW: Peripheral nerve lesion produces increased levels of major histocompatibility complex antigens in the central nervous system. *J Neuroimmunol* 21:117–123, 1989
6. Streit WJ, Kreutzberg GW: Response of endogenous glial cells to motor neuron degeneration induced by toxic ricin. *J Comp Neurol* 268:248–263, 1988
7. Tikka T, Fiebich BL, Goldsteins G, Keinanen R, Koistinaho J: Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by

- inhibiting activation and proliferation of microglia. *J Neurosci* 21:2580–2588, 2001
8. Levison SW, McCarthy KD: Astroglia in culture. In *Culturing Nerve Cells*. 1st ed. Banker GA, Goslin K, Eds. Cambridge, MA, MIT Press, 1991, p. 309–336
 9. Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. *Nucleic Acids Res* 29: e45, 2001
 10. Romanko MJ, Rothstein RP, Levison SW: Neural stem cells in the subventricular zone are resilient to hypoxia/ischemia whereas progenitors are vulnerable. *J Cereb Blood Flow Metab* 24:814–825, 2004
 11. Rungger-Brandle E, Dosso AA, Leuenberger PM: Glial reactivity, an early feature of diabetic retinopathy. *Invest Ophthalmol Vis Sci* 41:1971–1980, 2000
 12. Zeng XX, Ng YK, Ling EA: Neuronal and microglial response in the retina of streptozotocin-induced diabetic rats. *Vis Neurosci* 17:463–471, 2000
 13. Thornalley PJ: Cell activation by glycated proteins: AGE receptors, receptor recognition factors and functional classification of AGEs. *Cell Mol Biol (Noisy-le-grand)* 44:1013–1023, 1998
 14. Griffin WS, Sheng JG, Royston MC, Gentleman SM, McKenzie JE, Graham DI, Roberts GW, Mrazek RE: Glial-neuronal interactions in Alzheimer's disease: the potential role of a "cytokine cycle" in disease progression. *Brain Pathol* 8:65–72, 1998
 15. Gebicke-Haerter PJ, Lieb K, Illies P, Berger M: [Microglia: mechanisms of activation and significance in pathogenesis of neuropsychiatric illnesses]. *Nervenarzt* 69:752–762, 1998
 16. Prineas JW, Kwon EE, Cho ES, Sharer LR: Continual breakdown and regeneration of myelin in progressive multiple sclerosis plaques. *Ann N Y Acad Sci* 436:11–32, 1984
 17. D'Amelio FE, Smith ME, Eng LF: Sequence of tissue responses in the early stages of experimental allergic encephalomyelitis (EAE): immunohistochemical, light microscopic, and ultrastructural observations in the spinal cord. *Glia* 3:229–240, 1990
 18. Kolson DL, Lavi E, Gonzalez-Scarano F: The effects of human immunodeficiency virus in the central nervous system. *Adv Virus Res* 50:1–47, 1998
 19. Funatsu H, Yamashita H, Noma H, Mimura T, Yamashita T, Hori S: Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. *Am J Ophthalmol* 133:70–77, 2002
 20. Armstrong D, Augustin AJ, Spengler R, Al-Jada A, Nickola T, Grus F, Koch F: Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker. *Ophthalmologica* 212: 410–414, 1998
 21. Limb GA, Webster L, Soomro H, Janikoun S, Shilling J: Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF- receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. *Clin Exp Immunol* 118:213–218, 1999
 22. Barouch FC, Miyamoto K, Allport JR, Fujita K, Bursell SE, Aiello LP, Luscinskas FW, Adamis AP: Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. *Invest Ophthalmol Vis Sci* 41:1153–1158, 2000
 23. Carmo A, Cunha-Vaz JG, Carvalho AP, Lopes MC: Effect of cyclosporin-A on the blood-retinal barrier permeability in streptozotocin-induced diabetes. *Mediators Inflamm* 9:243–248, 2000
 24. Jousen AM, Poulaki V, Mitsiades N, Kirchhof B, Koizumi K, Dohmen S, Adamis AP: Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. *FASEB J* 16:438–440, 2002
 25. Suzumura A, Sawada M, Yamamoto H, Marunouchi T: Effects of colony stimulating factors on isolated microglia in vitro. *J Neuroimmunol* 30:111–120, 1990
 26. Loughlin AJ, Woodroffe MN, Cuzner ML: Regulation of Fc receptor and major histocompatibility complex antigen expression on isolated rat microglia by tumour necrosis factor, interleukin-1 and lipopolysaccharide: effects on interferon-gamma induced activation. *Immunology* 75:170–175, 1992
 27. Basu A, Krady JK, Enterline JR, Levison SW: Transforming growth factor beta1 prevents IL-1beta-induced microglial activation, whereas TNF-alpha and IL-6-stimulated activation are not antagonized. *Glia* 40:109–120, 2002
 28. Patrizio M: Tumor necrosis factor reduces cAMP production in rat microglia. *Glia* 48:241–249, 2004
 29. Romeo G, Liu WH, Asnaghi V, Kern TS, Lorenzi M: Activation of nuclear factor-kappaB induced by diabetes and high glucose regulates a proapoptotic program in retinal pericytes. *Diabetes* 51:2241–2248, 2002
 30. Gehrmann J, Matsumoto Y, Kreutzberg GW: Microglia: intrinsic immunefector cell of the brain. *Brain Res Brain Res Rev* 20:269–287, 1995
 31. Colton CA, Gilbert DL: Production of superoxide anions by a CNS macrophage, the microglia. *FEBS Lett* 223:284–288, 1987
 32. Banati RB, Rothe G, Valet G, Kreutzberg GW: Detection of lysosomal cysteine proteinases in microglia: flow cytometric measurement and histochemical localization of cathepsin B and L. *Glia* 7:183–191, 1993
 33. Adamis AP, D'Amato RJ: Shedding light on diabetic retinopathy. *Ophthalmology* 102:1127–1128, 1995
 34. Shen WH, Zhou JH, Broussard SR, Johnson RW, Dantzer R, Kelley KW: Tumor necrosis factor alpha inhibits insulin-like growth factor I-induced hematopoietic cell survival and proliferation. *Endocrinology* 145:3101–3105, 2004
 35. Venters HD, Tang Q, Liu Q, VanHoy RW, Dantzer R, Kelley KW: A new mechanism of neurodegeneration: a proinflammatory cytokine inhibits receptor signaling by a survival peptide. *Proc Natl Acad Sci U S A* 96:9879–9884, 1999
 36. Abu El-Asrar AM, Desmet S, Meersschaert A, Dralands L, Missotten L, Geboes K: Expression of the inducible isoform of nitric oxide synthase in the retinas of human subjects with diabetes mellitus. *Am J Ophthalmol* 132:551–556, 2001
 37. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM: Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. *Curr Eye Res* 14:1045–1053, 1995
 38. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. *N Engl J Med* 331:1480–1487, 1994
 39. Barber AJ, Lieth E, Khin SA, Antonetti DA, Buchanan AG, Gardner TW: Neural apoptosis in the retina during experimental and human diabetes: early onset and effect of insulin. *J Clin Invest* 102:783–791, 1998
 40. Yrjanheikki J, Keinänen R, Pellikka M, Hokfelt T, Koistinaho J: Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. *Proc Natl Acad Sci U S A* 95:15769–15774, 1998
 41. Yrjanheikki J, Tikka T, Keinänen R, Goldsteins G, Chan PH, Koistinaho J: A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. *Proc Natl Acad Sci U S A* 96:13496–13500, 1999
 42. Zhang C, Lei B, Lam TT, Yang F, Sinha D, Tso MO: Neuroprotection of photoreceptors by minocycline in light-induced retinal degeneration. *Invest Ophthalmol Vis Sci* 45:2753–2759, 2004
 43. Friedlander RM: Apoptosis and caspases in neurodegenerative diseases. *N Engl J Med* 348:1365–1375, 2003
 44. Chen M, Ona VO, Li M, Ferrante RJ, Fink KB, Zhu S, Bian J, Guo L, Farrell LA, Hersch SM, Hobbs W, Vonsattel JP, Cha JH, Friedlander RM: Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. *Nat Med* 6:797–801, 2000
 45. Teng YD, Choi H, Onario RC, Zhu S, Desilets FC, Lan S, Woodard EJ, Snyder EY, Eichler ME, Friedlander RM: Minocycline inhibits contusion-triggered mitochondrial cytochrome c release and mitigates functional deficits after spinal cord injury. *Proc Natl Acad Sci U S A* 101:3071–3076, 2004